P3-062: Wood-smoke exposure as a survival predictor in non-small cell lung cancer with response to erlotinib: an open label phase II study

Abstract

TTP and OS were female gender, the absence of smoking history, and adenocarcinoma histology. As expected, those treated with Erlotinib in the first line setting had significantly longer TTP than further lines (7.4 vs. 4.4; p<0.001). In the multivariate analysis only non smoking history remained as predictive factor for longer TTP and survival (p<0.0001). Most frequent reported adverse events were rash (62.9%; 12.9% grade 3/4), asthenia (37.1%; 9.2% grade 3/4) and diarrhea (33.3%; 6.1% grade 3/4). Conclusions: This interim analysis of a subset of elderly patients with advanced or metastatic NSCLC treated with Erlotinib in a real-life clinical setting confirms the good tolerability and promising activity. It is worthwhile mentioning the benefit in survival obtained by chemonaïve elderly patients. Therefore Erlotinib is an effective treatment for elderly patients with advanced NSCLC, even as a first-line treatment. A randomized phase III study intended for elderly patients with Erlotinib is warranted.